Comparative speed of kill after treatment with Simparica™(sarolaner) and Advantix®(imidacloprid + permethrin) against induced infestations of Dermacentor reticulatus on dogs

Becskei, Csilla; Geurden, Thomas; Erasmus, Heidi; Cuppens, Otto; Mahabir, Sean P.; Six, Robert H.

doi:10.1186/s13071-016-1377-9

Cited by 7 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The absence of evidence of E. canis transmission to the permethrin group was attributed to permethrin preventing tick attachment. That conclusion is in conflict with another study which found that throughout a month following treatment there were more live ticks on permethrin-treated than on sarolaner-treated dogs [ 22 ]. Regardless, the speed with which ticks are killed is important, and the faster the death of the tick, or at least the faster feeding is completely stopped, the lower the probability of disease transmission.…”

Section: Discussioncontrasting

confidence: 64%

Laboratory evaluation of the speed of kill of lotilaner (Credelio™) against Ixodes ricinus ticks on dogs

Murphy¹,

Cavalleri²,

Seewald³

et al. 2017

Parasites Vectors

View full text Add to dashboard Cite

BackgroundWith the geographical expansion of tick species and increased recognition of pathogens they transmit, there is a requirement for safe and rapidly effective control measures for dogs. Lotilaner, a novel isoxazoline, is rapidly absorbed following administration of a flavored chewable tablet formulation (Credelio™), providing at least 98% efficacy for at least 1 month following assessments at 48 h post-treatment, and following subsequent challenges. A study was conducted to determine the speed with which lotilaner kills ticks.MethodsFrom 38 dogs, the 32 with the highest Ixodes ricinus counts from a Day -4 infestation were randomized among four groups: two groups were untreated controls, two received lotilaner tablets at a minimum dose rate of 20 mg/kg. Infestations with I. ricinus were performed on Days -2, 7, 14, 21, 28 and 35. Counts were completed 4 and 8 h post-treatment (Day 0), and 8 and 12 h following subsequent infestations. All live ticks were incubated for 24 h following removal from study dogs.ResultsAt 4 h post-treatment, there was a 69.8% reduction in geometric mean live tick counts in treated dogs compared to controls. After incubation, the reduction increased to 97.2%. At 8 h after treatment, pre- and post-incubation reductions were 99.2 and 100%, respectively. Following post-treatment challenges, post-incubation efficacy through Day 28 at 8 and 12 h was at least 94.3 and 98.0%, respectively, and was 85.7 and 94.2% at 8 and 12 h after the Day 35 challenge. Mean live tick counts in the lotilaner groups were significantly lower than in the control groups at all assessments through Day 35 at 8 (t (7) ≥ 9, P < 0.0001, Days 0 to 28; t (7) = 3.54, P ≤ 0.0095, Day 35) and 12 h post-treatment and after subsequent infestations (t (7) ≥ 10, P < 0.0001, all days). There were no treatment-related adverse events.ConclusionLotilaner at a minimum dose rate of 20 mg/kg began to kill ticks on dogs within 4 h of treatment and efficacy was 100% within 8 h. Lotilaner sustained a rapid kill of newly infesting I. ricinus through 35 days. By quickly killing ticks that infest dogs, lotilaner has potential to help limit the transmission of tick-borne pathogens.Electronic supplementary materialThe online version of this article (10.1186/s13071-017-2467-z) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussioncontrasting

confidence: 64%

Laboratory evaluation of the speed of kill of lotilaner (Credelio™) against Ixodes ricinus ticks on dogs

Murphy¹,

Cavalleri²,

Seewald³

et al. 2017

Parasites Vectors

View full text Add to dashboard Cite

show abstract

“…Sarolaner, a new member of the isoxazoline class, has proved to be effective against the main tick species that infest dogs in countries both within the European Union (EU) and in the USA. Although these studies demonstrated the efficacy of sarolaner against tick species in the genera Ixodes [21, 25–30], Amblyomma [20, 26, 27, 29], Rhipicephalus [22, 24–26, 28] and Dermacentor [23, 25, 26, 28, 29], to our knowledge no study to ascertain the efficacy against ticks from the genus Haemaphysalis has been reported.…”

Section: Discussionmentioning

confidence: 99%

“…Tick species against which Simparica™ have been evaluated include Amblyomma americanum [20, 26], Ixodes scapularis [21, 26, 27, 29, 30], Rhipicephalus sanguineus ( sensu latu ) [22], Rhipicephalus sanguineus ( sensu stricto ) [24–26, 28], Dermacentor reticulatus [23, 25, 28], Ixodes hexagonus [25, 28], Dermacentor variabilis [26, 29], Amblyomma maculatum [26, 27, 29] and Ixodes ricinus [25, 27, 28].…”

Section: Introductionmentioning

confidence: 99%

Immediate and persistent efficacy of sarolaner (Simparica™) against Haemaphysalis elliptica on dogs

et al. 2019

View full text Add to dashboard Cite

Background The southern African yellow dog tick, Haemaphysalis elliptica , occurs in eastern and southern Africa and adults infest domestic and wild carnivores. This tick species is also a vector of the highly virulent Babesia rossi pathogen, the causative agent of canine babesiosis in sub-Saharan Africa. Sustained high levels of efficacy of a parasiticide are not only important in protecting dogs against the direct effects of tick infestation, but also in reducing the risk of tick-borne diseases. Sarolaner (Simparica™ chewable tablets) has been reported to be effective against the major tick species infesting dogs in Europe and the USA, including representatives from the genera Amblyomma , Ixodes , Rhipicephalus and Dermacentor. Until now no efficacy evaluations have been reported against species of the genus Haemaphysalis . The objective of the study was to confirm the efficacy of a single 2 mg sarolaner/kg oral dose of Simparica™ against induced infestations with H. ( R. ) elliptica , an important parasite of dogs in southern Africa. Methods This blinded, randomised, single centre, placebo controlled efficacy study followed a parallel group design and was conducted on two groups consisting of eight purpose-bred dogs each. Animals were treated orally, once on Day 0, with either a placebo compound (Group 1) or Simparica™ (Group 2). Simparica™ was administered orally at a dose rate of 2 mg sarolaner/kg body weight. The dogs were infested with ticks on Days − 7, − 2, 5, 12, 19, 26 and 33, with removal counts conducted on Days − 5, 2, 7, 14, 21, 28 and 35. Results A single oral administration of Simparica™ (sarolaner) at a minimum dose of 2 mg/kg resulted in a 100% efficacy against existing infestations of H. ( R. ) elliptica on dogs and a 100% reduction in live ticks following weekly re-infestations for 35 days. Moreover, the immediate and persistent high levels of efficacy observed in this study for 35 days is consistent with those observed in previous studies against ticks in other genera. Conclusions The efficacy of sarolaner (Simparica™), administered orally to dogs at the minimum label dose of 2.0 mg/kg, was demonstrated against existing and weekly re-infestations of H . ( R .) elliptica for at least 5 weeks. Efficacy of 100% was achieved against existing infestations as well as weekly re-infestations.

show abstract

“…Sarolaner is known to be highly effective against ticks, with a persistent efficacy of at least five weeks after a single treatment at the minimum recommended label dose [ 22 ]. Furthermore, a single treatment with sarolaner provides efficacy within 24 h for five weeks against D. reticulatus [ 23 ]. As such, sarolaner treatment has the potential to prevent B. canis transmission, as it takes 48 to 72 h after tick attachment for B. canis to be transmitted from an infected tick [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the efficacy of sarolaner (Simparica®) in the prevention of babesiosis in dogs

et al. 2017

Self Cite

View full text Add to dashboard Cite

BackgroundCanine babesiosis is a clinically significant emerging vector-borne disease caused among others by the protozoan Babesia canis. The efficacy of sarolaner (Simparica®; Zoetis; at the minimum recommended label dose of 2.0 mg per kg bodyweight) in the prevention of babesiosis was evaluated in twenty-four dogs randomly allocated to either a placebo-treated group or one of two sarolaner-treated groups. At 21 or 28 days after treatment administration, dogs were infested with 50 ± 4 Dermacentor reticulatus ticks of which 25% were confirmed to be infected with Babesia canis. Blood samples were collected from each dog prior to tick infestation and weekly thereafter until 49 days after infestation. The blood was assayed for B. canis antibodies using an indirect immunofluorescence test (IFAT) and for B. canis DNA by PCR assay. A dog was a priori defined as B. canis-positive if it tested positive by both IFAT and PCR at any time during the study.ResultsNo treatment-related adverse reactions were recorded during the study. All placebo-treated animals displayed clinical signs due to babesiosis and tested positive on both IFAT and PCR. None of the sarolaner-treated animals displayed any clinical symptoms or tested positive on both IFAT and PCR, resulting in a 100% efficacy in the prevention of canine babesiosis (P = 0.0002).ConclusionWhen given 21 or 28 days before tick infestation, a single treatment with sarolaner at the minimum recommended label dose of 2.0 mg per kg body weight prevented the transmission of B. canis by D. reticulatus to dogs.

show abstract

Comparative speed of kill after treatment with Simparica™(sarolaner) and Advantix®(imidacloprid + permethrin) against induced infestations of Dermacentor reticulatus on dogs

Cited by 7 publications

References 16 publications

Laboratory evaluation of the speed of kill of lotilaner (Credelio™) against Ixodes ricinus ticks on dogs

Laboratory evaluation of the speed of kill of lotilaner (Credelio™) against Ixodes ricinus ticks on dogs

Immediate and persistent efficacy of sarolaner (Simparica™) against Haemaphysalis elliptica on dogs

Evaluation of the efficacy of sarolaner (Simparica®) in the prevention of babesiosis in dogs

Contact Info

Product

Resources

About